Japan
Research Article
Circulating Tumor Cells as Prognostic Marker in Japanese patients with Kras Wild-type Metastatic Colorectal Cancer Receiving Panitumumab after
Progression on Cetuximab
Author(s): Yoshihito Ohhara, Satoshi Matsusaka, Toshiyasu Watanabe, Eiji Shinozaki, Mitsukuni Suenaga, Nobuyuki Mizunuma and Kiyohiko HatakeYoshihito Ohhara, Satoshi Matsusaka, Toshiyasu Watanabe, Eiji Shinozaki, Mitsukuni Suenaga, Nobuyuki Mizunuma and Kiyohiko Hatake
Background: Panitumumab has a high affinity for epidermal growth factor receptor. Its utility as a salvage therapy is unknown in cetuximab-resistant colorectal cancer. We assessed the prognostic and predictive role of circulating tumor cells (CTCs) in KRAS wild-type metastatic Colorectal Cancer (mCRC) patients treated with panitumumab after progression on cetuximab.
Methods: Panitumumab (6 mg/kg every 2 weeks) was administered as salvage therapy in a patient with cetuximab-resistant mCRC. The CTC count in whole blood at baseline was determined using immunomagnetics.
Results: Nineteen patients were enrolled in the study between July 2010 and March 2011. Five patients had Stable Disease (SD) with a response rate of 0%. Four patients reached long-SD, which was defined as continuous SD of more than 120 days. All of these fou.. Read More»
DOI:
10.4172/2157-7099.1000204
Journal of Cytology & Histology received 2476 citations as per Google Scholar report